GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for mesothelioma later on—according to research presented at the European Lung Cancer Conference. Alessandra Curioni Fontecedro MD, a senior physician in the department of oncology at University Hospital, Zurich explained to Oncology Times reporter Peter Goodwin how the molecular signatures of sensitivity to therapies targeting checkpoint inhibition pathways were not disturbed by prior chemotherapy.
You may also like...
Blood test for free tumour DNA could guide breast cancer therapy 3 Apr, 2013 Combining Checkpoint Inhibition With Other Therapies for Lung Cancer 22 Apr, 2015 Low Cost Screening Could Halve Stillbirths Due To Syphilis 20 Jul, 2011 Low Dose Rate Prostate Brachytherapy Doubled Cancer-Free Survival: ASCENDE-RT Study Finding 28 Apr, 2015
- Previous story Combining Checkpoint Inhibition With Other Therapies for Lung Cancer
- Next story CD8+ Cell Infiltration for Prognosis in Non-Small Cell Lung Cancer; Checkpoint Inhibition 2nd/3rd-line in Mesothelioma
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014